Loxo's targeted drug helps variety of advanced cancers in small study

June 3 (Reuters) - Three quarters of patients with a wide variety of advanced cancers responded to a Loxo Oncology Inc therapy that targets a specific genetic defect, according to data from a small study presented on Saturday at the year's most important oncology meeting.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News